Due to all of these data, abnormal STON2 expression was associated with intraperitoneal metastasis and recurrence, as well as a poor OS in ovarian cancer patients, suggesting that STON2 overexpression is associated with a poor prognosis. This evidence concerns the gene STON2 and ovarian carcinoma.